阳光诺和：投资者开放日展现创新实力 绘制医药研发新蓝图

Group 1 - The core viewpoint of the articles highlights Sunlight Nuohe's innovative capabilities and growth potential in the pharmaceutical research and development sector, showcasing its integrated business ecosystem of "R&D services + pipeline cultivation + new quality industrial chain" [1] - The company has several innovative products in the R&D phase, covering various therapeutic areas such as autoimmune diseases, pain management, cardiology, central nervous system, oncology, metabolism, and respiratory diseases [1] - Sunlight Nuohe is committed to a dual-driven strategy of "independent innovation + technology transfer," establishing an international standard R&D platform and enhancing its industrial collaboration network to help domestic pharmaceutical companies overcome technical barriers and accelerate import substitution [1] Group 2 - The company is aligning with the trends in biomedicine, leveraging technological breakthroughs, policy support, and market demand, and has established a self-owned peptide innovation drug library screening system [2] - Currently, three innovative drugs have entered clinical stages, including STC007 for postoperative pain, which is in Phase II and soon to enter Phase III, and STC008 targeting cancer cachexia, which has completed Phase IA and is about to start Phase IB [2] - In the field of modified new drug development, the company focuses on sustained-release formulations and high-end formulations, with multiple technology platforms working together to design personalized sustained-release technologies [2] Group 3 - The company has made significant progress in its transdermal delivery research platform, with experience in gel patches and hot melt adhesives, and has partnered with Japan's KANEKA to introduce advanced transdermal patch technology [3] - Sunlight Nuohe is actively exploring the small nucleic acid drug field, which has substantial development potential, and is conducting in-depth research on chemical modifications and delivery systems for small nucleic acid drugs [3] - The company aims to enhance its R&D capabilities by absorbing global cutting-edge technologies and strives to secure a position in the global pharmaceutical market while contributing to the competitiveness of China's pharmaceutical industry [3]